Without urgent intervention, Kenya risks a surge in new HIV infections, which currently stand at 16,752 annually, NSDCC said.

Fiji health authorities are scrambling to stem an outbreak of HIV, as growing meth use and alarming needle-sharing trends accelerate the spread of the virus.

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term protection. If this yearly injection is approved and widely implemented, it ...